|
A HIGH PERFORMANCE
LIQUID CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF LJP 394
IN PLASMA AND SERUM.
L. Leggett, et al.
Presented at the
Annual Meeting of the American Association of Pharmaceutical Scientists
Oct. 27-31, 1996
Seattle, WA.
REDUCTION OF ANTI-DS
DNA ANTIBODIES USING LJP 394 IN PATIENTS WITH LUPUS.
Bonnie Hepburn, et al.
Presented at The American College of Rheumatology's 60th National
Meeting
Oct. 21, 1996
Orlando, FL.
SOLUTION STRUCTURE
OF A PEPTIDE FROM A PHAGE DISPLAY LIBRARY USING ANTI-CARDIOLIPIN
ANTIBODY: A b2GPI EPITOPE MIMIC.
D.S. Sem
Presented at the
American Society for Biochemistry and Molecular Biology meeting
June 2-6, 1996
New Orleans, LA.
A DOSE-RANGING
STUDY OF LJP 394, A NOVEL THERAPEUTIC AGENT FOR THE TREATMENT OF
SYSTEMIC LUPUS ERYTHEMATOSUS.
J. Cash, et al.
Presented at the
26th Scandinavian Congress of Rheumatology Conference
May 31 - June 3, 1996
Reykjavik, Iceland.
SPECIFIC ANTI-dsDNA
B CELL TOLERANCE IN VIVO
Stephen M. Coutts, et al.
Presented at the
B Lymphocytes and Autoimmunity Conference
May 21-25, 1996
Prague, The Czech Republic.
`
|
PHARMACOLOGICAL
INTERVENTION IN ANTIBODY MEDIATED DISEASE.
S.M. Coutts, et al.
Published in
Lupus (1996) 5, 158-159.
|